Menu Back to Future-of-Evidence-and-Smart-Health-Conference

Overview

Following the success of the Future of Evidence and Digital Health Workshops, we now transfer these topics to a new conference in the EMEA region – the DIA Future of Evidence and Smart Health Conference. Combining regulatory and science perspectives in a unique forum, this conference discusses opportunities and implementation strategies within the EU data and digital landscape – to support regulators, industry, and patients. Explore latest developments in data usage and data storage, innovative approaches to integrated evidence, and how artificial intelligence and machine learning can transform drug development. The conference will gear you up to drive actionable outcomes and contribute to advancing the EU regulatory space.

The conference program follows two main tracks:

Real-world Evidence (RWE)

RWE data is a valuable source to help optimize clinical trial design and support decision-making for regulators, physicians, and other healthcare providers. We explore how to define the quality of different types of RWE sources and how to best approach a unified framework for clinical data collection. Understand how various stakeholders are leveraging RWE to advance healthcare knowledge and decision-making processes, which are increasingly in the hands of artificial intelligence tools.

Digital Health

With a deep dive into the fast-evolving digital healthcare ecosystem, you will be introduced to novel wearables and data collection methods. You further get insights into new formats of digital intervention in health. In interdisciplinary sessions, we approach hot topics like the Dynamic Dossier in the cloud, rapid reviews, and digital therapeutics which could help fulfill unmet medical needs caused by limitations in traditional therapies.


Featured topics

  • Application of AI & ML in Drug Development and Approval
  • Regulatory Landscape RWE and Digital Health - Challenges and Opportunities
  • EU Data Landscape
  • Real-World Evidence Data Sources and Data Quality
  • Innovative approaches to integrated evidence
  • Innovative Design Using Real-World Evidence and Novel End Points
  • Blockchain in Drug Development
  • RCT Duplicate
  • Cloud based systems for data storage

Who should attend?

    Professionals involved in:
  • Clinical operations and clinical development
  • Data Management, Privacy and Science
  • Data Science, data and analytics
  • R&D big data
  • Real World Evidence
  • Regulatory Innovation and Regulatory Science
  • Digital Health and Solutions
  • Patient Advocacy
  • Innovation
  • Policy
  • Epidemiology
  • Artificial Intelligence and Machine Learning
  • Market Access & Reimbursement

Program Committee

  • Thomas  Brookland, MSc
    Thomas Brookland, MSc Personalised Healthcare Policy Strategy Leader
    F. Hoffmann-La Roche Ltd., Switzerland
  • Adrian  Cassidy, PhD, MSc
    Adrian Cassidy, PhD, MSc Global Head of RWE and Data Science
    Novartis, Switzerland
  • Michael  Lees, MA
    Michael Lees, MA Chief Operating Officer and Head of Market Access Strategy
    PHMR Ltd, United Kingdom
  • Solène  Thieffry, MSc
    Solène Thieffry, MSc Global RWE Policy Lead
    UCB, Belgium
  • Emma  Du Four, MBA
    Emma Du Four, MBA Head of International Regulatory Policy
    Abbvie, United Kingdom
  • Cécile Mathilde Ollivier, MS
    Cécile Mathilde Ollivier, MS OCM Director - Regulatory Science Europe
    Critical Path Institute (C-Path), Netherlands
Load More

Contact us

Trouble connecting on the day of the event?

Send Email
+41 61 225 51 51


Registration Questions?

Send Email
+41 61 225 51 51

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download